[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633565":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":10,"responsibleParty":29,"collaborators":10,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":35,"acronym":36,"eligibilityCriteria":37,"healthyVolunteers":33,"sex":38,"minAge":39,"maxAge":10,"enrollmentInfo":40,"targetDuration":43,"studyType":44,"phases":10,"briefSummary":45,"conditions":46,"keywords":10,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":10},{"fullName":5,"class":6},"University of Aarhus","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Reirradiation",null,"All patients treated with reirradiation with the aim of local control",[13],"Radiation: Reirradiation",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":10},"RADIATION","reirradiation with all available modalities can be included",[9],[20,26],{"name":21,"role":22,"phone":23,"phoneExt":24,"email":25},"Hanna R Mortensen, PhD, MD","CONTACT","92432382","22154394","hanna.mortensen@auh.rm.dk",{"name":27,"role":22,"phone":10,"phoneExt":10,"email":28},"Camilla JS Kronborg, PhD, MD","cam.kro@auh.rm.dk",{"type":30,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100633565","prospective-registry-for-oncologic-reirradiation-prior-dk-100633565",false,"NCT07528339","Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK)","PRIOR","Inclusion Criteria:\n\n* High dose reirradiation (reirradiation type I or II or repeat organ irradiation delivered with the aim of local control)\n\nRead Danish (for questionnaires + patient information)\n\nLife expectancy due to age and co-morbidity of ≥6 months.\n\nThe general condition must be sufficient to tolerate persistent significant side effects\n\nHistological or imaging verified loco-regional recurrence, solitary oligo metastasis or new primary\n\nAge ≥18 years\n\nSigned informed consent, updated annually\n\nExpected follow up physical, by video, by phone or likely contact at a relevant oncological department\n\nAvailable dose plan(s) from primary (and prior) radiotherapy course(s) (with 3D reconstruction of previous plans, available port film, or drawings). Multiple re-treatments are allowed (new inclusion and baseline registration)\n\nExclusion Criteria:\n\n* The primary and reirradiation treatments may not be quasi-simultaneous (i.e. the two treatments should be planned independently)\n\nInability to attend full course of radiotherapy\n\nPurpose of radiotherapy is ONLY palliation of symptoms","ALL","18 Years",{"count":41,"type":42},500,"ESTIMATED","5 Years","OBSERVATIONAL","The study aims to provide a setup for collecting radiotherapy-related toxicity data, loco-regional control, and overall survival data for all Danish cancer patients undergoing reirradiation with high dose intention or with the aim of local tumour control; with the ultimate aim of providing safe reirradiation to a larger group of patients. To build a reirradiation cohort database for future research",[47],"Radiotherapy Side Effect","NOT_YET_RECRUITING","2026-04-07",{"date":51,"type":52},"2026-04-14","ACTUAL",{"date":54,"type":42},"2026-04-01",{"date":56,"type":42},"2037-03-31",{"name":5,"class":6}]